{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:19:53Z","timestamp":1788265193582,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008867","name":"Education of Zhejiang Province","doi-asserted-by":"crossref","award":["Y202045537"],"award-info":[{"award-number":["Y202045537"]}],"id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The best antiviral treatment for chronic hepatitis B (CHB) poses a complex challenge. The treatment effect of the combination of nucleoside analogues (NAs) and pegylated interferon alpha (PegIFN) was still in debate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied patients treated with NAs and PegIFN-2b at our institution from November 2019 to January 2022. Logistic regression identified independent factors influencing clinical cure. The predictive accuracy of the formula was assessed using the Receiver operating characteristic (ROC) curve at different time points (before therapy, 12 weeks, and 24 weeks into treatment).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 120 patients were enrolled in the final analysis. Among the cohort of patients under study, 71 (59.1%) patients had clinical cure while 49 (40.9%) patients did not. Hepatitis B surface antigen (HBsAg) at baseline and age were the powerful variables predicting the clearance of HBsAg. The area under the ROC (AUC) was 0.907 for pre-treatment predictive model, 0.958 for 12-week predictive model and 0.747 for 24-week predictive model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provided predictive formulas for clinical cure, offering valuable insights for CHB treatment. PegIFN and NAs exhibited efficacy. Future research that explores additional factors, such as HBV genotype, in a larger cohort study is needed.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-024-10057-0","type":"journal-article","created":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T12:01:34Z","timestamp":1728820894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Shuang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-He","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,13]]},"reference":[{"issue":"8","key":"10057_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"YC Hsu","year":"2023","unstructured":"Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20(8):524\u201337.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10057_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","volume":"2","author":"JH Kao","year":"2002","unstructured":"Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2(7):395\u2013403.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10057_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-2003-37590","volume":"23","author":"G Fattovich","year":"2003","unstructured":"Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003;23(1):47\u201358.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10057_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","volume":"48","author":"G Fattovich","year":"2008","unstructured":"Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335\u201352.","journal-title":"J Hepatol"},{"key":"10057_CR5","doi-asserted-by":"publisher","first-page":"1075916","DOI":"10.3389\/fimmu.2022.1075916","volume":"13","author":"JR Zheng","year":"2022","unstructured":"Zheng JR, Wang ZL, Feng B. Hepatitis B functional cure and immune response. Front Immunol. 2022;13:1075916.","journal-title":"Front Immunol"},{"key":"10057_CR6","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"MF Yuen","year":"2018","unstructured":"Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035.","journal-title":"Nat Rev Dis Primers"},{"issue":"10003","key":"10057_CR7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546\u201355.","journal-title":"Lancet"},{"issue":"1","key":"10057_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398.","journal-title":"Hepatol Int"},{"issue":"12","key":"10057_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/jvh.12341","volume":"21","author":"GL Wong","year":"2014","unstructured":"Wong GL, Wong VW, Chan HL. Combination therapy of interferon and nucleotide\/nucleoside analogues for chronic hepatitis B. J Viral Hepat. 2014;21(12):825\u201334.","journal-title":"J Viral Hepat"},{"issue":"11","key":"10057_CR10","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/jmv.24534","volume":"88","author":"L Boglione","year":"2016","unstructured":"Boglione L, Cariti G, Di Perri G, D\u2019Avolio A. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. J Med Virol. 2016;88(11):1953\u20139.","journal-title":"J Med Virol"},{"issue":"13","key":"10057_CR11","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3748\/wjg.v26.i13.1525","volume":"26","author":"FP Wu","year":"2020","unstructured":"Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen\u2009\u2264\u20091500 IU\/mL: an observational study. World J Gastroenterol. 2020;26(13):1525\u201339.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10057_CR12","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1007\/s10620-018-5251-9","volume":"63","author":"SH Ahn","year":"2018","unstructured":"Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, et al. Hepatitis B Surface Antigen loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 analysis. Dig Dis Sci. 2018;63(12):3487\u201397.","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10057_CR13","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.4254\/wjh.v12.i11.1076","volume":"12","author":"T Broquetas","year":"2020","unstructured":"Broquetas T, Garcia-Retortillo M, Mic\u00f3 M, Canillas L, Puigveh\u00ed M, Ca\u00f1ete N, et al. Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. World J Hepatol. 2020;12(11):1076\u201388.","journal-title":"World J Hepatol"},{"issue":"1","key":"10057_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13089-024-00369-2","volume":"16","author":"T Heller","year":"2024","unstructured":"Heller T, Phiri V, Kumwenda T, Mzumara W, Vinikoor MJ, Rambiki E, et al. Point-of-care ultrasound to inform antiviral treatment initiation in chronic hepatitis B virus infection in low-resource settings - the PUSH protocol. Ultrasound J. 2024;16(1):18.","journal-title":"Ultrasound J"},{"issue":"3","key":"10057_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hep Intl. 2012;6(3):531\u201361.","journal-title":"Hep Intl"},{"issue":"1","key":"10057_CR16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/HEP.0000000000000524","volume":"79","author":"P Jiang","year":"2024","unstructured":"Jiang P, Jia H, Qian X, Tang T, Han Y, Zhang Z, et al. Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-\u03b1 in patients with chronic hepatitis B. Hepatology. 2024;79(1):167\u201382.","journal-title":"Hepatology"},{"issue":"1","key":"10057_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","volume":"6","author":"P Hu","year":"2018","unstructured":"Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, et al. HBsAg loss with Peg-interferon Alfa-2a in Hepatitis B patients with partial response to Nucleos(t)ide Analog: new switch study. J Clin Transl Hepatol. 2018;6(1):25\u201334.","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"10057_CR18","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/hep.29213","volume":"66","author":"Z Cao","year":"2017","unstructured":"Cao Z, Liu Y, Ma L, Lu J, Jin Y, Ren S, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017;66(4):1058\u201366.","journal-title":"Hepatology"},{"issue":"4","key":"10057_CR19","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/hep.22760","volume":"49","author":"MR Brunetto","year":"2009","unstructured":"Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49(4):1141\u201350.","journal-title":"Hepatology"},{"issue":"4","key":"10057_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2169\/internalmedicine.5432-20","volume":"60","author":"N Itokawa","year":"2021","unstructured":"Itokawa N, Atsukawa M, Tsubota A, Shimada N, Toyoda H, Takaguchi K, et al. Factors Associated with Hepatitis B Surface Antigen Kinetics and responses in Pegylated Interferon Alpha-2a Monotherapy for patients with chronic Hepatitis B. Intern Med. 2021;60(4):507\u201316.","journal-title":"Intern Med"},{"key":"10057_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12985-015-0453-7","volume":"12","author":"K Masaki","year":"2015","unstructured":"Masaki K, Suzuki F, Hara T, Kawamura Y, Sezaki H, Hosaka T, et al. Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection. Virol J. 2015;12:225.","journal-title":"Virol J"},{"issue":"11","key":"10057_CR22","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1136\/gut.2004.062208","volume":"54","author":"HJ Flink","year":"2005","unstructured":"Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut. 2005;54(11):1604\u20139.","journal-title":"Gut"},{"issue":"2","key":"10057_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/gutjnl-2014-308546","volume":"65","author":"R Fan","year":"2016","unstructured":"Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016;65(2):313\u201320.","journal-title":"Gut"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10057-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T15:29:32Z","timestamp":1732894172000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10057-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,13]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10057"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10057-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,13]]},"assertion":[{"value":"8 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been authorized by the ethics committee of the Third Affiliated Hospital of Wenzhou Medical University (YJ2024052). Written informed consent was obtained from all individuals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1149"}}